Immunomethylomic profiles of long-term head and neck squamous cell carcinoma survivors on immune checkpoint inhibitors

被引:1
|
作者
Lee, Min Kyung [1 ]
Zhang, Ze [1 ]
Sehgal, Kartik [2 ]
Butler, Rondi [3 ,4 ]
Stolrow, Hannah [1 ]
Ramush, Geat [3 ,4 ]
Shirai, Keisuke [5 ]
Koestler, Devin C. [6 ]
Salas, Lucas A. [1 ]
Wiencke, John K. [7 ]
Haddad, Robert [2 ]
Kelsey, Karl T. [3 ,4 ]
Christensen, Brock C. [1 ,8 ,9 ]
机构
[1] Geisel Sch Med Dartmouth, Dept Epidemiol, Lebanon, NH 03755 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[3] Brown Univ, Dept Epidemiol, Sch Publ Hlth, Providence, RI 02903 USA
[4] Brown Univ, Dept Pathol & Lab Med, Sch Med, Providence, RI 02903 USA
[5] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA
[6] Univ Kansas, Med Ctr, Dept Biostat & Data Sci, Kansas City, KS 66103 USA
[7] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
[8] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03755 USA
[9] Geisel Sch Med Dartmouth, Dept Community & Family Med, Lebanon, NH 03755 USA
基金
美国国家卫生研究院;
关键词
DNA methylation; head and neck squamous cell carcinoma; immune checkpoint inhibitors; immune profiles; immunomethylomics; methylation cytometry; MEMORY T-CELLS; DNA METHYLATION;
D O I
10.1080/17501911.2024.2343274
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Aim: This study addresses the challenge of predicting the response of head and neck squamous cell carcinoma (HNSCC) patients to immunotherapy. Methods: Using DNA methylation cytometry, we analyzed the immune profiles of six HNSCC patients who showed a positive response to immunotherapy over a year without disease progression. Results: There was an initial increase in CD8 T memory cells and natural killer cells during the first four cycles of immunotherapy, which then returned to baseline levels after a year. Baseline CD8 T cell levels were lower in HNSCC immunotherapy responders but became similar to those in healthy subjects after immunotherapy. Conclusion: These findings suggest that monitoring fluctuations in immune profiles could potentially identify biomarkers for immunotherapy response in HNSCC patients.
引用
收藏
页码:799 / 807
页数:9
相关论文
共 50 条
  • [41] RADICAL NECK DISSECTION FOR SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - EARLY AND LONG-TERM RESULTS OF TREATMENT
    BENDER, MD
    MONTGOMERY, ACV
    SHAW, HJ
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 1985, 67 (01) : 47 - 50
  • [42] Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors
    Hobday, Sara B.
    Brody, Robert M.
    Kriegsman, Barry
    Basu, Devraj
    Newman, Jason
    Cohen, Roger B.
    Lukens, J. Nicholas
    Singh, Aditi
    D'Avella, Christopher A.
    Sun, Lova
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2022, 148 (10) : 918 - 926
  • [43] Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma
    Sridharan, Vishwajith
    Rahman, Rifaquat M.
    Huang, Raymond Y.
    Chau, Nicole G.
    Lorch, Jochen H.
    Uppaluri, Ravindra
    Haddad, Robert, I
    Hannah, Glenn J.
    Schoenfeld, Jonathan D.
    ORAL ONCOLOGY, 2018, 85 : 29 - 34
  • [44] Impact of therapeutic EGFR inhibition on immune checkpoint blockade in head and neck squamous cell carcinoma
    Rogers, Laura M.
    Espinosa-Cotton, Madelyn M.
    Simons, Andrean L.
    Weiner, George J.
    CANCER RESEARCH, 2016, 76
  • [45] Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma
    Ngamphaiboon, Nuttapong
    Chairoungdua, Arthit
    Dajsakdipon, Thanate
    Jiarpinitnun, Chuleeporn
    ORAL ONCOLOGY, 2023, 145
  • [46] Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Saleh, Khalil
    Daste, Amaury
    Martin, Nicolas
    Pons-Tostivint, Elvire
    Auperin, Anne
    Herrera-Gomez, Ruth Gabriela
    Baste-Rotllan, Neus
    Bidault, Francois
    Guigay, Joel
    Le Tourneau, Christophe
    Saada-Bouzid, Esma
    Even, Caroline
    EUROPEAN JOURNAL OF CANCER, 2019, 121 : 123 - 129
  • [47] Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Suzuki, Shinsuke
    Toyoma, Satoshi
    Kawasaki, Yohei
    Koizumi, Koh
    Iikawa, Nobuko
    Shiina, Kazuhiro
    Endo, Tentaro
    Abe, Tomoe
    Kouga, Teppei
    Yamada, Takechiyo
    MEDICINA-LITHUANIA, 2021, 57 (11):
  • [48] Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
    Economopoulou, Panagiota
    Anastasiou, Maria
    Papaxoinis, George
    Spathas, Nikolaos
    Spathis, Aris
    Oikonomopoulos, Nikolaos
    Kotsantis, Ioannis
    Tsavaris, Onoufrios
    Gkotzamanidou, Maria
    Gavrielatou, Niki
    Vagia, Elena
    Kyrodimos, Efthymios
    Gagari, Eleni
    Giotakis, Evangelos
    Delides, Alexander
    Psyrri, Amanda
    CANCERS, 2021, 13 (02) : 1 - 15
  • [49] Changes in serum lactate dehydrogenase as a prognostic factor in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors
    Lee, Woo Hee
    Takenaka, Yukinori
    Hosokawa, Kiyohito
    Eguchi, Hirotaka
    Suzuki, Masami
    Fukusumi, Takahito
    Suzuki, Motoyuki
    Inohara, Hidenori
    ACTA OTO-LARYNGOLOGICA, 2024, 144 (5-6) : 398 - 403
  • [50] Cerebral Infarction as a Rare Adverse Event of Immune Checkpoint Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma: A Case Series
    Inoue, Takahiro
    Kumai, Takumi
    Ohara, Kenzo
    Takahara, Miki
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)